These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 19074844)

  • 1. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2008 Dec; 7(12):3670-84. PubMed ID: 19074844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy for cancer: an update.
    Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR
    Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for cancer: current and emerging concepts.
    Jain RK
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
    Jain RK
    Science; 2005 Jan; 307(5706):58-62. PubMed ID: 15637262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of antiangiogenic therapies.
    Hudis CA
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):26-31. PubMed ID: 15934500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and future directions for angiogenesis-based cancer therapies.
    Scappaticci FA
    J Clin Oncol; 2002 Sep; 20(18):3906-27. PubMed ID: 12228212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly discovered angiogenesis inhibitors and their mechanisms of action.
    Miao ZH; Feng JM; Ding J
    Acta Pharmacol Sin; 2012 Sep; 33(9):1103-11. PubMed ID: 22922347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic inhibitors: a new therapeutic strategy in oncology.
    Gasparini G; Longo R; Toi M; Ferrara N
    Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
    Loges S; Mazzone M; Hohensinner P; Carmeliet P
    Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
    Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
    Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The possible role of chemotherapy in antiangiogenic drug resistance.
    Bocci G; Loupakis F
    Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic agents in cancer therapy.
    Lenz HJ
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy.
    Blagosklonny MV
    Cancer Biol Ther; 2005 Dec; 4(12):1307-10. PubMed ID: 16322683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
    Bottsford-Miller JN; Coleman RL; Sood AK
    J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.